Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):702-3. doi: 10.1161/01.ATV.0000062990.62034.64.
No abstract available

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Body Constitution
  • C-Reactive Protein / analysis*
  • Coronary Artery Disease / prevention & control
  • Gemfibrozil / pharmacology
  • Gemfibrozil / therapeutic use*
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / etiology
  • Hypolipidemic Agents / pharmacology
  • Hypolipidemic Agents / therapeutic use*
  • Interleukin-6 / blood
  • Male
  • Metabolic Syndrome / blood*
  • Middle Aged
  • Obesity / blood*
  • Tumor Necrosis Factor-alpha / analysis

Substances

  • Hypolipidemic Agents
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Gemfibrozil